Association Between
            <i>AXIN1</i>
            Gene Polymorphisms and Epithelial Ovarian Cancer in Chinese Population

Zhang, Yan; Wang, Yanyun; Huang, Xingming; Li, Qin; Li, Kai; You, Di; Song, Yaping; Su, Minggang; Zhou, Bin; Wang, Wei

doi:10.2217/bmm-2018-0306

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overwhelming majority of selected biomarker studies investigated different tissue-based biomarkers using a variety of technical research methods. The selected tissue prognostic biomarkers can be divided into immunohistochemical biomarkers (68.77%) , DNA biomarkers (3.95%) [159,[233][234][235][236][237][238][239][240][241] and RNA biomarkers (27.28%) . The prognostic value of 172 protein biomarkers was evaluated by immunohistochemistry in 174 studies (Table 2).…”

Section: Tissue-based Prognostic Biomarkersmentioning

confidence: 99%

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Liu¹,

Wu²,

Wang³

2021

J. Cancer

View full text Add to dashboard Cite

Ovarian cancer is a serious threat to women's health; its early diagnosis rate is low and prone to metastasis and recurrence. The current conventional treatment for ovarian cancer is a combination of platinum and paclitaxel chemotherapy based on surgery. The recurrence and progression of ovarian cancer with poor prognosis is a major challenge in treatment. With rapid advances in technology, understanding of the molecular pathways involved in ovarian cancer recurrence and progression has increased, biomarker-guided treatment options can greatly improve the prognosis of patients. This review systematically discusses and summarizes existing and new information on prognostic factors and biomarkers of ovarian cancer, which is expected to improve the clinical management of patients and lead to effective personalized treatment.

show abstract

Section: Tissue-based Prognostic Biomarkersmentioning

confidence: 99%

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Liu¹,

Wu²,

Wang³

2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Zhang et al indicated the effects of rs12921862 AC and the rs1805105 GA genotypes on epithelial ovarian cancer (EOC) susceptibility. In addition, they showed that EOC patients with rs12921862 CC genotype improved by the Kaplan–Meier survival curves for the overall survival 27 . In a meta‐analysis performed on eight studies on the association between AXIN2 rs2240308 polymorphism and overall cancer risk (2015), Gong et al showed decreased cancer risk in the homozygous, heterozygous, dominant, and allelic (T vs. C) models 28 .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, they showed that EOC patients with rs12921862 CC genotype improved by the Kaplan-Meier survival curves for the overall survival. 27 In a meta-analysis performed on eight studies on the association between AXIN2 rs2240308 polymorphism and overall cancer risk (2015), Gong et al showed decreased cancer risk in the homozygous, heterozygous, dominant, and allelic (T vs. C) models. 28 Similar to the finding of the present study, Pu et al showed an increased risk of cell renal cell carcinoma (ccRCC) in individuals carrying rs1805105 GA/GG genotypes and rs12921862 AA genotype.…”

Section: Discussionmentioning

confidence: 99%

Association of AXIN1 rs12921862 C/A and rs1805105 G/A and CTSB rs12898 G/A polymorphisms with papillary thyroid carcinoma: A case–control study

Saljooghi

Heidari

Saravani

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Papillary thyroid cancer (PTC) is the most common type of thyroid cancer which its precise etiology remains unknown. However, environmental and genetic factors contribute to the etiology of PTC. Axis inhibition protein 1 (Axin1) is a scaffold protein that exerts its role as a tumor suppressor. In addition, Cathepsin B (Ctsb) is a cysteine protease with higher expression in several types of tumors. Therefore, the aim of this study was to investigate the possible association of AXIN1 rs12921862 C/A and rs1805105 G/A and CTSB rs12898 G/A polymorphisms with PTC susceptibility. Materials & Methods In total, 156 PTC patients and 158 sex‐, age‐, and BMI‐matched control subjects were enrolled in the study. AXIN1 rs12921862 C/A and rs1805105 G/A and CTSB rs12898 G/A polymorphisms were genotyped using the PCR–RFLP method. Results There was a relationship between AXIN1 rs12921862 C/A polymorphism and an increased risk of PTC in all genetic models except the overdominant model. The AXIN1 rs1805105 G/A polymorphism was associated with an increased PTC risk only in codominant and overdominant models. The frequency of AXIN1 Ars12921862 Ars1805105 haplotype was higher in the PTC group and also this haplotype was associated with an increased risk of PTC. Moreover, the AXIN1 rs12921862 C/A polymorphism was not associated with PTC clinical and pathological findings, but AXIN1 rs1805105 G/A polymorphism was associated with almost three folds of larger tumor size (≥1 cm). There was no association between CTSB rs12898 G/A polymorphism and PTC and its findings. Conclusion The AXIN1 rs12921862 C/A and rs1805105 G/A polymorphisms were associated with PTC. AXIN1 rs1805105 G/A polymorphism was associated with higher tumor size.

show abstract

Development of Biomarker

Pal

2021

Springer Protocols Handbooks

View full text Add to dashboard Cite

Association Between AXIN1 Gene Polymorphisms and Epithelial Ovarian Cancer in Chinese Population

Cited by 4 publications

References 38 publications

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Association of AXIN1 rs12921862 C/A and rs1805105 G/A and CTSB rs12898 G/A polymorphisms with papillary thyroid carcinoma: A case–control study

Development of Biomarker

Contact Info

Product

Resources

About